Halogen Lysinol HIV Protease Inhibitors
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current HIV protease inhibitors are not suitable for all HIV-infected subjects due to adverse effects and the development of resistance, necessitating the need for new compounds that can effectively inhibit HIV protease for prophylaxis and treatment of HIV and AIDS.
Innovation Solution
Development of halogen lysinol compounds and their pharmaceutically acceptable salts, specifically defined by Formula I, which act as HIV protease inhibitors for the prophylaxis and treatment of HIV infection and the delay in the progression of AIDS.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing HIV protease inhibitors are used for treatment, then HIV protease inhibition is achieved, but adverse effects and resistance development occur
Solution Approach 1:
The patent modifies the chemical structure of known protease inhibitors by incorporating halogenated lysinol moieties and varying substituents (R1-R6 groups) to alter pharmacological properties. This structural parameter change aims to maintain protease inhibition while reducing adverse effects and resistance development through optimized molecular characteristics
Solution Approach 2:
The invention creates composite molecular structures by combining halogenated lysinol frameworks with various aromatic and aliphatic substituent groups. These composite structures integrate multiple functional elements that work synergistically to achieve improved therapeutic profiles compared to single-structure inhibitors
2Productivity
If current protease inhibitor therapies are administered, then HIV viral load reduction is achieved, but subject tolerance is compromised
Solution Approach 1:
The patent introduces specific local modifications to the inhibitor molecule, particularly at the lysinol portion with halogen substitution and specific substituent patterns. These localized structural changes target specific interactions with the protease active site while minimizing off-target effects, thereby improving subject tolerance without sacrificing antiviral productivity
3Duration of action of stationary object
If existing protease inhibitors are used, then HIV infection treatment is provided, but resistance development limits long-term efficacy
Solution Approach 1:
The patent employs a series of related compounds with varying substituent patterns that can be dynamically selected based on resistance profiles. The flexible molecular framework allows adaptation to different resistance mutations, enabling sustained treatment efficacy over time through strategic compound selection rather than relying on a single static inhibitor
Data Source
AI summary
Compounds of Formula I are disclosed wherein R1, R2, R3A, R3B, R4A, R4B, R5A, R5B, R6A, R6B, R7, R8 and R9 are defined herein. The compounds encompassed by Formula I include compounds which are HIV protease inhibitors and other compounds which can be metabolized in vivo to HIV protease inhibitors. The compounds and their pharmaceutically acceptable salts are useful for the prophylaxis or treatment of infection by HIV and the prophylaxis, treatment, or delay in the onset of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.